Peringkat dalam Saham
#35289
IMV Inc. is a clinical-stage biotechnology company dedicated to the development... IMV Inc. is a clinical-stage biotechnology company dedicated to the development of innovative immunotherapies. The company utilizes its proprietary DPX immune-educating technology platform to create a portfolio of treatments for various solid and hematological cancers. Its leading investigational drug, maveropepimut-S, is a DPX-based immunotherapy designed to target cancer cells that express survivin. Maveropepimut-S is currently undergoing Phase II clinical trials for diffuse large B-cell lymphoma, ovarian cancer, and specific bladder, liver, and microsatellite instability-high tumors, with Phase I trials also active for breast cancer. Beyond its primary candidate, IMV is also advancing DPX-SurMAGE, which is in Phase I clinical trials for bladder cancer, and is developing DPX-COVID-19 and DPX-RSV to address infectious diseases. Originally founded in 2000 as Immunovaccine Inc., the company adopted the name IMV Inc. in May 2018 and operates from its headquarters in Dartmouth, Canada.
Harga Saham
$0.82959892
Terakhir disinkronkan: 2023-05-23
Kapitalisasi Pasar
$4.16M
Perubahan (1 hari)
-0.04%
Perubahan (1 tahun)
0.00%
Perdagangan IMV Inc. (IMV)
Harga IMV dengan kapitalisasi pasar B
Kapitalisasi pasar dari IMV Inc.(IMV)
Kapitalisasi Pasar: $4.16M
Per August 2026, IMV Inc. memiliki kapitalisasi pasar sebesar $4.16M. Ini menjadikan IMV Inc. sebagai perusahaan 35289th paling bernilai di dunia menurut data kami. Kapitalisasi pasar adalah nilai total saham beredar dari perusahaan publik dan biasanya digunakan untuk mengukur seberapa besar nilai sebuah perusahaan.
Riwayat kapitalisasi pasar IMV Inc. dari 2012 hingga 2026
IMV dibandingkan dengan 5 teratas stocks paling populer
| Harga IMV |
|
Aset B |
Pasar B |
Hasil |
|
|
|
|
$5.452T
|
+131,076,102.29%
|
|
|
|
|
$4.490T
|
+107,950,940.04%
|
|
|
|
|
$4.162T
|
+100,074,320.56%
|
|
|
|
|
$3.676T
|
+88,388,142.13%
|
|
|
|
|
$2.833T
|
+68,113,157.05%
|
